Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Another Mucositis Therapy for Myeloma
Another Mucositis Therapy for Myeloma
Add a new mucositis therapy for myeloma patients undergoing chemotherapy. I won’t blame you if you think the six posts about mucositis therapies linked below are extreme coverage of the topic. Keep in mind that I troll the internet daily looking for studies that I think might help MM patients and survivors.
One specific research study focusing on MM patients receiving melphalan-based ASCT found that 75% of patients developed OM. In this study, 21% of the patients experienced severe OM (Grades 3-4).
Therefore, the therapies listed that have been shown to reduce or eliminate oral mucositis can undoubtedly help MM patients.
- Oral Mucositis in Myeloma
- Mucositis Cost Containment
- Managing Oral Mucositis
- Oral Mucositis Therapies-
- Myeloma, Mucositis- Prevent, Treat
- Stem Cell Transplant Side Effects-MM-Oral Mucositis
Do All Patients Get Mouth Sores During a Stem Cell Transplant? How to Lower Your Risk | #myeloma
No single OM therapy is 100% effective, so I recommend using several therapies at the same time. For example, a compounded mouthwash containing acyclovir combined with curcumin supplementation, combined with chewing ice. Something like that.
Remember that MM is a marathon not a sprint. I’ve learned that managing short-term, long-term and late-stage side effects is just as important as managing your MM.
Email me at David.PeopleBeatingCance@gmail.com to learn more about managing MM with both conventional and non-conventional therapies.
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
The role of compounded mouthwash with or without acyclovir in managing chemotherapy-induced oral mucositis in cancer patients: a randomized controlled trial
Background Chemotherapy-induced oral mucositis (CIOM) is a prevalent and debilitating condition observed in cancer patients, especially in those suffering from hematologic malignancies. The present study assessed the efficacy of a compounded mouthwash, both with and without the addition of acyclovir, in the management of CIOM.
Although various treatment options exist for this condition, their effectiveness remains limited, underscoring the necessity for innovative approaches to the formulation of compounded mouthwashes for improved management of CIOM.
Methods A prospective, double-blind, randomized controlled study design with 110 patients with newly diagnosed acute leukemia or who underwent hematopoietic stem cell transplantation.
Participants were allocated randomly to either the acyclovir-containing mouthwash group (Arm A) or the control group without acyclovir (Arm B). The incidence, duration, and severity of mucositis were assessed via standardized scale, the World Health Organization (WHO) scale for oral mucositis.
Results The incidence of mucositis was significantly lower in Arm A (25.5%) compared to Arm B (45.5%), with a p-value of 0.028. Furthermore, the duration of mucositis was significantly shorter in Arm A, exhibiting a median duration of 4.5 days, in contrast to a median of 7.5 days observed in Arm B (p = 0.01).
Grade 3 mucositis was absent in the acyclovir group, whereas there were five cases reported in Arm B (p = 0.045). Logistic regression analysis corroborated the protective effect of the acyclovir-containing mouthwash against the development of mucositis, yielding an odds ratio (OR) of 2.444 with a p-value of 0.03.
Conclusions
The incorporation of acyclovir into compounded mouthwash significantly reduced the incidence, severity, and duration of oral mucositis in patients undergoing chemotherapy, indicating its potential for expanded clinical application.
Further large-scale studies are warranted to validate these findings and to standardize mouthwash formulations for institutional utilization. Trial registration This trial was approved by the Institutional Research Board (IRB) under the code R.23.05. 2176.R1. Date: 20 May 2023.
mucositis therapy for myeloma mucositis therapy for myeloma mucositis therapy for myeloma